For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks
Teovska Mitrevska, N., Eleftheriadou, V
Medical Condition Contrave is FDA-approved for weight management in people with a body mass index (BMI) of more than 30, or a BMI of more than 27 with another weight-related condition, like high blood pressure, Type 2 diabetes, or high cholesterol
Read the source-cited BPC-157 research overview and evidence limitations.
[PubMed] [Google Scholar] 16.Rodwell VW, Nordstrom JL, Mitschelen JJ
With 15+ years of dermatology experience, he leads with precision and compassion
